The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk
Open accessAbstract
Importance: Some cholesteryl ester transfer protein (CETP) inhibitors lower low-density lipoprotein cholesterol (LDL-C) levels without reducing cardiovascular events, suggesting that the clinical benefit of lowering LDL-C may depend on how LDL-C is lowered. Objective: To estimate the association between changes in levels of LDL-C (and other lipoproteins) and the risk of cardiovascular events related to variants in the CETP gene, both alone and in combination with variants in the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) gene. Design, Setting, and Participants: Mendelian randomization analyses evaluating the association between CETP and HMGCR scores, changes in lipid and lipoprotein levels, and the risk of cardiovascular events involving 102 837 participants from 14 cohort or case-control studies conducted in North America or the United Kingdom between 1948 and 2012. The associations with cardiovascular events were externally validated in 189 539 participants from 48 studies conducted between 2011 and 2015. Exposures: Differences in mean high-density lipoprotein cholesterol (HDL-C), LDL-C, and apolipoprotein B (apoB) levels in participants with CETP scores at or above vs below the median. Main Outcomes and Measures: Odds ratio (OR) for major cardiovascular events. Results: The primary analysis included 102 837 participants (mean age, 59.9 years; 58% women) who experienced 13 821 major cardiovascular events. The validation analyses included 189 539 participants (mean age, 58.5 years; 39% women) with 62 240 cases of coronary heart disease (CHD). Considered alone, the CETP score was associated with higher levels of HDL-C, lower LDL-C, concordantly lower apoB, and a corresponding lower risk of major vascular events (OR, 0.946 [95% CI, 0.921-0.972]) that was similar in magnitude to the association between the HMGCR score and risk of major cardiovascular events per unit change in levels of LDL-C (and apoB). When combined with the HMGCR score, the CETP score was associated with the same reduction in LDL-C levels but an attenuated reduction in apoB levels and a corresponding attenuated nonsignificant risk of major cardiovascular events (OR, 0.985 [95% CI, 0.955-1.015]). In external validation analyses, a genetic score consisting of variants with naturally occurring discordance between levels of LDL-C and apoB was associated with a similar risk of CHD per unit change in apoB level (OR, 0.782 [95% CI, 0.720-0.845] vs 0.793 [95% CI, 0.774-0.812]; P = .79 for difference), but a significantly attenuated risk of CHD per unit change in LDL-C level (OR, 0.916 [95% CI, 0.890-0.943] vs 0.831 [95% CI, 0.816-0.847]; P < .001) compared with a genetic score associated with concordant changes in levels of LDL-C and apoB. Conclusions and Relevance: Combined exposure to variants in the genes that encode the targets of CETP inhibitors and statins was associated with discordant reductions in LDL-C and apoB levels and a corresponding risk of cardiovascular events that was proportional to the attenuated reduction in apoB but significantly less than expected per unit change in LDL-C. The clinical benefit of lowering LDL-C levels may therefore depend on the corresponding reduction in apoB-containing lipoprotein particles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, Mendelian randomization studies demonstrated that the reduction in cardiovascular risk associated with genetic variation in clearance and processing of apoB-containing lipoproteins, including LDL particles as well as TG-rich VLDL particles and their remnants, was correlated with the change of concentration of these particles as measured by apoB rather than the cholesterol mass carried”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [79]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, the results of this study are consistent with a recent mendelian randomization study that demonstrated that the causal effect of LDL particles on the risk of cardiovascular disease appears to be determined by the concentration of circulating LDL particles as measured by ApoB rather than by the mass of cholesterol carried by those particles as measured by LDL-C.23”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [23]
In the citing paper
“Fibrates are associated with a slightly increased risk of pancreatitis [321].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [321]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bowden, J., Davey Smith, G., & Burgess, S. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv080 · Cited by 9,816
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Mendelian randomization: genetic anchors for causal inference in epidemiological studies
Davey Smith, G., & Hemani, G. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu328 · Cited by 4,677
Self-citationFerence, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citationBiological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Self-citationEffects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationWiller (2013) · doi:10.1038/ng.2797 · Cited by 2,983
Self-citationA comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease
the CARDIoGRAMplusC4D Consortium (2015) · Nature Genetics · doi:10.1038/ng.3396 · Cited by 2,447
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Self-citationLarge-scale association analysis identifies new risk loci for coronary artery disease
The CARDIoGRAMplusC4D Consortium, Deloukas, P., DIAGRAM Consortium, CARDIOGENICS Consortium, MuTHER Consortium, Wellcome Trust Case Control Consortium, Kanoni, S., Willenborg, C., Farrall, M., Assimes, T. L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2480 · Cited by 1,614
Research works printed but not linked: 4
- [10]10. Hovingh GK, Kastelein JJ, van Deventer SJ, et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP). Lancet. 2015;386(9992):452-460.
- [19]19. Burgess S, Dudbridge F, Thompson SG. Combining information on multiple instrumental variables in mendelian randomization. Stat Med. 2016;35(11):1880-1906.
- [20]20. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments. Int J Epidemiol. 2015;44(2):512-525.
- [22]22. Moore C, Sambrook J, Walker M, et al. The INTERVAL trial to determine whether intervals between blood donations can be safely and acceptably decreased to optimise blood supply. Trials. 2014;15:363.
Cited by
Sorted by citations
Items 201–300 of 304
Quo Vadis after AEGIS: New Opportunities for Therapies Targeted at Reverse Cholesterol Transport?
Lan, N. S. R., & Watts, G. F. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01281-3 · Cited by 5
Nicholls, S. J., & Nelson, A. J. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2362644 · Cited by 6
Self-citationAn update on trials of novel lipid-lowering drugs
Wierzbicki, A. S., Reynolds, T., & Viljoen, A. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000518 · Cited by 5
Ha, E. T., Cohen, M. C., Fields, P. J., Daele, J. V., & Gaeta, T. J. (2019) · Journal of diagnostic medical sonography · doi:10.1177/8756479319886572 · Cited by 5
Structure of New Ferroverdins Recruiting Unconventional Ferrous Iron Chelating Agents
Martinet, L., Baiwir, D., Mazzucchelli, G., & Rigali, S. (2022) · Biomolecules · doi:10.3390/biom12060752 · Cited by 6
The Contribution of Vascular Proteoglycans to Atherothrombosis: Clinical Implications
Drysdale, A., Unsworth, A. J., White, S. J., & Jones, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411854 · Cited by 7
Discovery and Exploration of Lipid-Modifying Drug Targets for ALS by Mendelian Randomization
Jiang, Z., Gu, X., Su, W., Duan, Q., Yin, K., Ren, Y., Wang, Y., Cao, B., & Chen, Y. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04007-9 · Cited by 5
Kar, S., Brenner, H., Giles, G. G., Huo, D., Milne, R. L., Rennert, G., Simard, J., Zheng, W., Burgess, S., & Pharoah, P. D. P. (2019) · International Journal of Epidemiology · doi:10.1093/ije/dyz047 · Cited by 5
Multitrait genetic-phenotype associations to connect disease variants and biological mechanismsPreprint
Julienne, H., Laville, V., McCaw, Z. R., He, Z., Guillemot, V., Lasry, C., Ziyatdinov, A., Vaysse, A., Lechat, P., Ménager, H., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.26.172999 · Cited by 5
CETP Inhibitors: Back With a New Target
Nicholls, S. J., Ray, K. K., Nelson, A. J., & Kastelein, J. J. P. (2026) · Circulation Research · doi:10.1161/circresaha.125.327271 · Cited by 4
Self-citationZheng, W., Yang, W., Zhang, Q., Yang, X.-H., Cai, D.-B., Hu, J., Ungvari, G. S., Ng, C. H., Binder, M. D., Ning, Y., et al. (2018) · Europe PMC (PubMed Central) · doi:10.11919/j.issn.1002-0829.217156 · Cited by 4
Baragetti, A. (2022) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.09 · Cited by 4
Evolving concepts of low‐density lipoprotein: From structure to function
Chen, C., Sawamura, T., Akhmedov, A. T., Tsai, M., Akyol, Ö., Kakino, A., Chiang, H., Kraler, S. C., & Lüscher, T. F. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70019 · Cited by 6
The year in cardiology 2017: prevention
Nordestgaard, B. G., Cosentino, F., Landmesser, U., & Laufs, U. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx766 · Cited by 4
Self-citationBlack, D. M., Miller, M. J., Heinonen, T. M., & Zhang, G. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001093 · Cited by 4
Jones, P. R., Rajalahti, T., Resaland, G. K., Aadland, E., Steene‐Johannessen, J., Anderssen, S. A., Bathen, T. F., Andreassen, T., Kvalheim, O. M., & Ekelund, U. (2022) · International Journal of Behavioral Nutrition and Physical Activity · doi:10.1186/s12966-022-01244-w · Cited by 6
Genotype‐driven NPC1L1 and PCSK9 inhibition and reduced risk of periodontitis
Baumeister, S., Holtfreter, B., Reckelkamm, S. L., Kocher, T., Alayash, Z., Ehmke, B., Baurecht, H., & Nolde, M. (2022) · Journal Of Clinical Periodontology · doi:10.1111/jcpe.13719 · Cited by 4
What Guidelines Say About Risk Reduction: Major Data on the Link Between Lipid Lowering and Outcomes
Thanassoulis, G., Welsh, R. C., & Hegele, R. A. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.04.023 · Cited by 4
Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs
Takata, K., & Nicholls, S. J. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0312-1 · Cited by 4
Self-citationInflammatory joint diseases and atherosclerosis: time to look beyond the ‘lipid paradox’
Mackey, R. H., Kuller, L. H., & Moreland, L. W. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000620 · Cited by 4
An update on emerging drugs for the treatment of hypercholesterolemia
Nelson, A. J., Bubb, K. J., & Nicholls, S. J. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.2009801 · Cited by 4
Self-citationGenetically increased serum calcium levels reduce Alzheimer’s disease riskPreprint
Jiang, Q., Hu, Y., Jin, S., & Liu, G. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/255059 · Cited by 4
Merriman, T. R. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.002138 · Cited by 3
Lyall, D. M., Ward, J., Banach, M., Smith, G. D., Gill, J. M. R., Pell, J. P., Holmes, M. V., & Sattar, N. A. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/335877 · Cited by 4
Self-citationO’Keeffe, L. M., Tilling, K. M., Bell, J. A., Lee, M. A., Lawlor, D. A., Smith, G. D., & Kearney, P. M. (2021) · medRxiv · doi:10.1101/2021.07.28.21261181 · Cited by 4
Self-citationLyu, L., Kao, C., Su, J., Yu, Y., Zhang, X., Lyu, J., Che, J., & Zhang, J. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-025-02852-8 · Cited by 4
Ábel, T., Benczúr, B., & Csajbókné, É. C. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-025-03965-w · Cited by 3
Effect of selenium nanoparticle on lipid profile in local Awassi male lambs
Hamzah, A. M., & Dawood, T. N. (2024) · Open Veterinary Journal · doi:10.5455/ovj.2024.v14.i5.10 · Cited by 3
Sun, L., Zhang, Q., Shi, M., Liu, Y., Zhu, Z., Zhang, J., Peng, H. Y., Wang, A., Chen, J., Xu, T., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.036544 · Cited by 3
Cardiology Meets Personalized Lifestyle Medicine.
Bland, J. S. (2017) · PubMed Central · Cited by 3
von Eckardstein, A., März, W., & Laufs, U. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1516-2731 · Cited by 4
Self-citationShui, X., Wen, Z., Dong, R., Chen, Z., Tang, L., Tang, W., Wu, Z., & Chen, L. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01872-6 · Cited by 3
He, J., Lin, Z., Song, C., Yuan, S., Bian, X., Li, B., Ma, W., & Dou, K. (2024) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2024.08.004 · Cited by 3
Yu, X., Yuan, Y., Dong, X., Xier, Z., Ma, L., Peng, H., Li, G., & Yang, Y. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2529565 · Cited by 3
Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk
Jones‐O’Connor, M., & Natarajan, P. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0741-4 · Cited by 3
Emerging therapies in dyslipidaemias
Catapano, A. L. (2023) · Vascular Pharmacology · doi:10.1016/j.vph.2023.107229 · Cited by 3
Self-citationDarabi, M., Zakiev, E., & Kontush, A. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_18 · Cited by 3
Sobczyk, M. K., Zheng, J., Smith, G. D., & Gaunt, T. R. (2022) · medRxiv · doi:10.1101/2022.04.11.22273633 · Cited by 3
Self-citationThe two faces of cholesteryl ester transfer protein inhibitors
Pirillo, A., & Catapano, A. L. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001017 · Cited by 2
Self-citationInia, J. A., Zhang, L. H., Keijzer, N., Worms, N., van Nieuwkoop, A., Ditmarsch, M., Kleer, M. D., Jukema, J. W., Kastelein, J. J. P., Szarek, M. J., et al. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101028 · Cited by 2
Self-citationTu, Z., Wei, Y., Liao, Y., Wan, Z., Zhou, Z., & Guo, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1816199 · Cited by 2
Epidemiology of Atherosclerotic Cardiovascular Disease
Hirahatake, K. M., Dicklin, M. R., & Maki, K. C. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_5 · Cited by 2
Study of effect modifiers of genetically predicted CETP reduction
Legault, M., Barhdadi, A., Gamache, I., Lemaçon, A., Perreault, L. L., Grenier, J., Sylvestre, M., Hussin, J., Rhainds, D., Tardif, J., et al. (2023) · Genetic Epidemiology · doi:10.1002/gepi.22514 · Cited by 2
Metabolites and coronary heart disease: A two sample Mendelian randomization
Yang, S., Gao, F., Zhu, Z., Zhang, T., & Zhang, W. (2025) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2025.200365 · Cited by 2
The 2018 ACC/AHA Lipid Guidelines: A Little More or Less Canadian?
Thanassoulis, G., Grégoire, J. C., & Pearson, G. J. (2019) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.03.003 · Cited by 2
High-Density Lipoprotein and High-Density Lipoprotein Cholesterol
Riggs, K. A., & Rohatgi, A. K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54835-9.00006-5 · Cited by 2
Prinzip der mendelschen Randomisierung und Anwendung in der kardiovaskulären Medizin
Katzmann, J. L., Ference, B. A., & Laufs, U. (2019) · Der Kardiologe · doi:10.1007/s12181-019-0328-z · Cited by 2
Self-citationSafety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk
Zhang, D., Wu, H., & Gong, S. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2510693 · Cited by 2
Zhu, Q., Tan, Y., Zou, X., & Lu, L. (2023) · Scientific Reports · doi:10.1038/s41598-023-49771-1 · Cited by 1
Lipoprotein(a) in atherosclerotic cardiovascular disease, type 2 diabetes, and liver disease
Williams, K. L., Augustine, M., Sujakhu, E., Magadia, J., Crawford, L., Knott, A., Hamilton, S., & Obiaka, U. (2024) · Progress in Pediatric Cardiology · doi:10.1016/j.ppedcard.2024.101775 · Cited by 1
Choi, H., Oh, S. J., Jo, Y. H., Park, Y. H., Park, Y. H., Yang, T., Doh, J., Hong, Y. J., Ahn, K. T., Cho, J. M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-00298-7 · Cited by 2
Statins as potential adjuvant therapy in lung cancer: a narrative review
Tian, Y., Li, J., & Yang, X. (2025) · Journal of Thoracic Disease · doi:10.21037/jtd-2025-66 · Cited by 1
Obicetrapib and CETP inhibition: An exception to the rule?
Cariou, B., & Moulin, P. (2025) · Med · doi:10.1016/j.medj.2025.100780 · Cited by 1
Hu, F., Wu, R., Zhao, X., Zhao, Y.-K., Zhou, J., Hu, B., Li, A., & Sun, Y. (2025) · Translational Stroke Research · doi:10.1007/s12975-025-01367-9 · Cited by 3
Cholesteryl Ester Transfer Protein Inhibitors: State of the Science
Nejabat, M., Katsiki, N., Mukherjee, D., Hadizadeh, F., & Sahebkar, A. (2026) · Current Cardiology Reports · doi:10.1007/s11886-025-02317-5 · Cited by 1
Kheirkhah, A., Maio, S. D., Coassin, S., Schönherr, S., Lamina, C., Forer, L., Kronenberg, F., & Schachtl‐Riess, J. F. (2026) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2026.101564 · Cited by 2
Cholesterol Ester Transfer Protein Inhibitor Review
Hu, J. C. Y., & Walker, S. E. (2017) · Hospital Pharmacy · doi:10.1177/0018578717729669 · Cited by 1
Nicholls, S. J., & Nelson, A. J. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-00323-3 · Cited by 1
Self-citationYan, M., Huang, Y., Liu, X., Chen, C., Zhou, D., Huang, Y., & Feng, Y. (2023) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2023.07.012 · Cited by 1
Khomtchouk, B. B., Sun, P., Maggio, Z. A., Ditmarsch, M., Kastelein, J. J. P., & Davidson, M. H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1359780 · Cited by 1
Self-citationTada, H., Furukawa, A., Kojima, N., Usui, S., Sakata, K., Kawashiri, M., & Takamura, M. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120417 · Cited by 1
Márk, L., Harangi, M., & Paragh, G. (2018) · Orvosi Hetilap · doi:10.1556/650.2018.30961 · Cited by 1
Nicholls, S. J. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz284 · Cited by 1
Self-citationCETP inhibition in the REVEAL trial: could we aim higher?
Sahebkar, A., Mikhailidis, D. P., & Banach, M. (2020) · Archives of Medical Science · doi:10.5114/aoms.2020.97968 · Cited by 1
Lawler, P. R., & Mora, S. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2017.280172 · Cited by 1
Liu, Z., Ye, T., Sun, B., Schooling, M., & Tchetgen, E. T. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2009.14484 · Cited by 1
Lipids, lipid-modifying drug Target genes and Bladder cancer: a Mendelian randomization studyPreprint
Pan, W.-K., Xianjing, H., Ren, S., Hu, C., & Lin, B. (2023) · Research Square · doi:10.21203/rs.3.rs-3541205/v1 · Cited by 1
Shi, J., Shringarpure, S., Hinds, D. A., Auton, A., & Holmes, M. V. (2024) · medRxiv · doi:10.1101/2024.07.24.24310950 · Cited by 2
Rare protein-disrupting variants in CETP and protection against vascular eventsPreprint
Landfors, F., de Kleer, M., Kastelein, J. J. P., & Chorell, E. (2024) · medRxiv · doi:10.1101/2024.12.02.24318306 · Cited by 1
Self-citationHIGH-DENSITY LIPOPROTEINS AND CARDIOVASCULAR DISEASE
Nicholls, S. J., Brown, H., & Bubb, K. J. (2020) · EMJ Cardiology · doi:10.33590/emjcardiol/20-00038 · Cited by 1
Self-citationКанорский, С. Г., Мамедов, М. Н., & Гегамович, О. Р. (2018) · Kardiologiia · doi:10.18087/cardio.2018.11.10208
Hypertriglyzeridämie und HDL-Mangel
von Eckardstein, A. (2017) · CardioVasc · doi:10.1007/s15027-017-1275-x
The year in cardiology 2017: prevention
Nordestgaard, B. G., Cosentino, F., Landmesser, U., & Laufs, U. (2018) · Cardiologia Croatica · doi:10.15836/ccar2018.79
Self-citationPerrot, N., Moschetta, D., Boekholdt, S. M., Valerio, V., Martinsson, A., Capoulade, R., Mass, E., Clavel, M.-A. A., Wareham, N. J., Christian Dina, C., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/560458
Sodium transport in frog skin: a student laboratory experiment in epithelial physiology.
Sernka, T. J. (1981) · PubMed
Sun, J., Zhang, H., Zhang, Y., Wang, L., Oh, J. R., Sun, B., & Liu, G. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/737585
Challenges in constructing genetic instruments for pharmacologic therapiesPreprint
Ference, B. A., Smith, G. D., Holmes, M. V., Catapano, A. L., Ray, K. K., & Nicholls, S. J. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2007.13115 · Cited by 1
Self-citationHow ApoB Measurements Could Improve Prevention of Cardiovascular Disease
Sniderman, A. D. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_29
Richardson, T. G., Wang, Q., Sanderson, E. C. M., Mahajan, A., McCarthy, M. I., Frayling, T. M., Ala‐Korpela, M., Sniderman, A. D., Smith, G. D., & Holmes, M. V. (2021) · Yearbook of pediatric endocrinology · doi:10.1530/ey.18.12.14
Self-citationYan, M., Liu, X., Huang, Y., Yu, Y., Zhou, D., & Feng, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-1039792/v1
Genetic Disorders of Lipoprotein Metabolism: Diagnosis and Management
Cupido, A. J., Stoekenbroek, R. M., & Kastelein, J. J. P. (2020) · Springer eBooks · doi:10.1007/978-3-030-45457-9_23
Self-citationJebari‐Benslaiman, S., Galicia-García, U., Larrea, A., Uribe, K. B., Martín, C., & Benito‐Vicente, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85857-1.00033-x
Li, F., Huang, F., Lu, Y., Wang, X., Li, M., Zhang, F., Jiang, H., Chen, J., & Lv, B. (2023) · Research Square · doi:10.21203/rs.3.rs-2683148/v1
Nicholls, S. J., & Nelson, A. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00029-7
Self-citationCETP and SGLT2 inhibitor combination therapy improves glycemic controlPreprint
Khomtchouk, B. B., Sun, P., Ditmarsch, M., Kastelein, J. J. P., & Davidson, M. H. (2023) · medRxiv · doi:10.1101/2023.06.13.23291357
Self-citationBorges, M. C., Haycock, P., Zheng, J., Hemani, G., Holmes, M. V., Smith, G. D., Hingorani, A. D., & Lawlor, D. A. (2022) · Figshare · doi:10.6084/m9.figshare.20057439
Self-citationHe, J., Lin, Z., Song, C., Yuan, S., Bian, X., Li, B., Ma, W., & Dou, K. (2024) · Revista Española de Cardiología · doi:10.1016/j.recesp.2024.08.013
Li, L., Hu, T., & Wang, D. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1552389
Bedre risikoprediksjon med ApoB eller non-HDL-kolesterol
Kalleklev, T., Larstorp, A. C. K., & Retterstøl, K. (2025) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.25.0139
Sawant, A., Griķe, I., & Vilne, B. (2025) · Mitochondrion · doi:10.1016/j.mito.2025.102069
Borges, M. C., Haycock, P. C., Zheng, J., Hemani, G., Holmes, M. V., Smith, G. D., Hingorani, A. D., & Lawlor, D. A. (2022) · Figshare · doi:10.6084/m9.figshare.20057442
Self-citationWu, Y., Xu, W., Guo, L., Li, W., Zhang, L., Gao, L., Zhu, C., Chen, S., Lin, L., & Wu, S. (2023) · Figshare · doi:10.6084/m9.figshare.23612475
Shui, X., Wen, Z., Dong, R., Chen, Z., Tang, L., Tang, W., Wu, Z., & Chen, L. (2023) · Figshare · doi:10.6084/m9.figshare.23916999
Shui, X., Wen, Z., Dong, R., Chen, Z., Tang, L., Tang, W., Wu, Z., & Chen, L. (2023) · Figshare · doi:10.6084/m9.figshare.23917002
Wu, Y., Xu, W., Guo, L., Li, W., Zhang, L., Gao, L., Zhu, C., Chen, S., Lin, L., & Wu, S. (2023) · Figshare · doi:10.6084/m9.figshare.23612478
Bell, J. A., Santos Ferreira, D. L., Fraser, A., Soares, A. L. G., Howe, L. D., Lawlor, D. A., Carslake, D., Smith, G. D., & O’Keeffe, L. M. (2021) · Figshare · doi:10.6084/m9.figshare.14100471
Self-citationShui, X., Wen, Z., Dong, R., Chen, Z., Tang, L., Tang, W., Wu, Z., & Chen, L. (2023) · Figshare · doi:10.6084/m9.figshare.23916996
Borges, M. C., Haycock, P. C., Zheng, J., Hemani, G., Holmes, M. V., Smith, G. D., Hingorani, A. D., & Lawlor, D. A. (2022) · Figshare · doi:10.6084/m9.figshare.20057445
Self-citationcHDL reevaluado: nuevos conocimientos y nuevo potencial en la farmacología cardiovascular
Fernández-Olmo, R., Cordero, A., Albarrán, O. G., Miranda, J. L., & Badimón, L. (2026) · REC CardioClinics · doi:10.1016/j.rccl.2025.12.004
Metadata
- Authors
- Ference, B. A., Kastelein, J. J. P., Ginsberg, H. N., Chapman, M. J., Nicholls, S. J., Ray, K. K., Packard, C. J., Laufs, U., Brook, R. D., Oliver-Williams, C., Butterworth, A. S., Danesh, J., Smith, G. D., Catapano, A. L., & Sabatine, M. S.
- Affiliations
- Wayne State University (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- Columbia University Irving Medical Center (US)
- Inserm (FR)
- South Australian Health and Medical Research Institute (AU)
- Imperial College London (GB)
- University of Glasgow (GB)
- Leipzig University (DE)
- University of Michigan (US)
- MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
- University of Cambridge (GB)
- University of Bristol (GB)
- University of Milan (IT)
- Brigham and Women's Hospital (US)
- Corresponding author
- Ference, Brian A.
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2017-09-12
- Volume
- 318
- Issue
- 10
- Pages
- 947
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC5710502
- OpenAlex
- W2749237115
- Cited by
- 304
- References
- 34
- Citations by year
- 2026: 13 · 2025: 23 · 2024: 23 · 2023: 34 · 2022: 28 · 2021: 41 · 2020: 43 · 2019: 46 · 2018: 37 · 2017: 15
- FWCI
- 39.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Apollo (University of Cambridge) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion, other-oa)
- Apollo
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Biogen
- NHS Blood and Transplant
- Regeneron Pharmaceuticals
- Wellcome Trust
- National Institute for Health and Care Research (NF-SI-0512-10165, MC_UU_12013/1)
- British Heart Foundation (CH/12/2/29428, RG/13/13/30194, RG/16/4/32218, RG/08/014/24067)
- Bupa Foundation
- European Commission (279143, 279233)
- University of Bristol (MC_UU_12013/1)
- Cambridge University Hospitals (3819-1516-29, BRC 2012-2017, 3819-1617-25, 146281)
- Evelyn Trust
- Medical Research Council (MC_UU_12013, MR/L003120/1, MR/M012816/1, MCUU12013/1, MR/P013880/1)
- Homerton College, University of Cambridge
- National Heart, Lung, and Blood Institute
- Fogarty International Center
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- cholesteryl ester transfer protein, statins, CETP inhibitors, LDL cholesterol, HDL cholesterol, apolipoprotein B, lipoprotein levels, cardiovascular risk, coronary artery disease, major adverse cardiovascular events, lipid-lowering therapy, Mendelian randomization
- MeSH terms
- Anticholesteremic Agents, Apolipoproteins B, Cardiovascular Diseases, Female, Humans, Hydroxymethylglutaryl CoA Reductases, Hypercholesterolemia, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Risk Factors, Genetic Variation, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cholesterol Ester Transfer Proteins, Mendelian Randomization Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
